Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Rating of “Moderate Buy” from Brokerages

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has received a consensus recommendation of “Moderate Buy” from the eleven research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $49.30.

CLDX has been the subject of a number of analyst reports. Wells Fargo & Company raised their price objective on shares of Celldex Therapeutics from $38.00 to $54.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. Barclays raised their price objective on shares of Celldex Therapeutics from $45.00 to $48.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Wolfe Research upgraded shares of Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price objective for the company in a research note on Monday, March 23rd. HC Wainwright restated a “buy” rating and set a $42.00 price objective on shares of Celldex Therapeutics in a research note on Monday, June 15th. Finally, UBS Group raised their price objective on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th.

Institutional Trading of Celldex Therapeutics

A number of large investors have recently made changes to their positions in the stock. Wellington Management Group LLP grew its stake in shares of Celldex Therapeutics by 39.3% in the fourth quarter. Wellington Management Group LLP now owns 8,079,608 shares of the biopharmaceutical company’s stock worth $219,442,000 after acquiring an additional 2,279,605 shares during the period. Vanguard Group Inc. grew its stake in shares of Celldex Therapeutics by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 4,027,407 shares of the biopharmaceutical company’s stock worth $109,384,000 after acquiring an additional 72,817 shares during the period. Bellevue Group AG grew its stake in shares of Celldex Therapeutics by 7.6% in the third quarter. Bellevue Group AG now owns 3,557,669 shares of the biopharmaceutical company’s stock worth $92,037,000 after acquiring an additional 250,100 shares during the period. Commodore Capital LP grew its stake in shares of Celldex Therapeutics by 7.8% in the second quarter. Commodore Capital LP now owns 3,450,000 shares of the biopharmaceutical company’s stock worth $70,208,000 after acquiring an additional 250,000 shares during the period. Finally, State Street Corp grew its stake in shares of Celldex Therapeutics by 19.5% in the fourth quarter. State Street Corp now owns 3,397,713 shares of the biopharmaceutical company’s stock worth $92,282,000 after acquiring an additional 555,579 shares during the period.

Celldex Therapeutics Stock Performance

NASDAQ:CLDX opened at $37.21 on Wednesday. The firm has a market cap of $2.92 billion, a P/E ratio of -8.73 and a beta of 0.95. Celldex Therapeutics has a fifty-two week low of $19.72 and a fifty-two week high of $39.16. The firm has a 50-day simple moving average of $32.18 and a two-hundred day simple moving average of $29.36.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.80 million. On average, equities research analysts predict that Celldex Therapeutics will post -4.36 EPS for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.